Clinical trials: Kidney Pancreas Transplant
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Type 1 Diabetes
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a…
- Trial name
- NCT00533442
- Testing
- Rapamycin, Mycophenolate Mofetil, Tacrolimus
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Miami
Pancreas Transplantation, Kidney Transplantation
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients.
- Trial name
- NCT00267150
- Testing
- Enteric-coated mycophenolate sodium (EC-MPS)
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Simultaneous Kidney and Pancreas Transplantation
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications.
- Trial name
- NCT01790594
- Testing
- Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit)
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Insufficiency
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
- Trial name
- NCT00580047
- Testing
- Zoledronic Acid, Calcium with vitamin D, Alendronate
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Nebraska
HIV, Kidney Transplant
Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients.
- Conditions
- HIV, Kidney Transplant, Liver Transplant
- Trial name
- HIVTR-EVE (NCT02429869)
- Testing
- everolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Nephrotoxicity
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant.
- Trial name
- NCT02103855
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Indiana University